approval
saveEVRYSDI (RISDIPLAM) — FDA approval
community read0 votes
Sponsor: GENENTECH INC. Form: FOR SOLUTION. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 10, 2026 · 236d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026 · 256d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026 · 256d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026 · 256d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 11, 2025 · 600d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 11, 2025 · 600d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalSep 17, 2024 · 747d ago
- approvalEVRYSDI (RISDIPLAM) — FDA approvalFeb 29, 2024 · 948d ago
same company · ±60 days · 6
- approvalEVRYSDI: EVRYSDI (RISDIPLAM) — FDA approvalFeb 10, 2026
- approvalEVRYSDI: EVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026
- approvalEVRYSDI: EVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026
- approvalEVRYSDI: EVRYSDI (RISDIPLAM) — FDA approvalJan 21, 2026
- approvalpolatuzumab vedotin: POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approvalMar 18, 2026
- approvaltrastuzumab emtansine: KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvalMar 26, 2026
comments(0)
5-min edit window · permanent after that